Patients w/ ischemic heart disease & those w/ risk factors for heart disease; HTN; hyperlipidemia, diabetes, smoking & in patients w/ peripheral arterial disease. Increased risk of serious CV thrombotic events, MI, & stroke. Not a substitute for acetylsalicylic acid for prophylaxis of CV thromboembolic diseases. Onset of new HTN or worsening of preexisting HTN. Closely monitor BP during initiation & throughout the course of therapy; patients w/ preexisting CHF or HTN; renal function in patients w/ advanced renal disease. Patients w/ compromised cardiac function, preexisting edema or other conditions predisposing to, or worsened by, fluid retention including those taking diuretic treatment or otherwise at risk of hypovolemia. Risk of developing GI complications (upper & lower GI perforations, ulcers or bleeds) in elderly, patients w/ CV disease; concomitant use w/ glucocorticoids, antiplatelet drugs (eg, aspirin), or other NSAIDs; alcohol use; those w/ prior history of, or active GI disease (eg, ulceration, GI bleeding or inflammatory conditions). Dehydrated patients; rehydrate patients prior to start of therapy. Anaphylactoid reactions. Discontinue at the 1st appearance of skin rash, mucosal lesions, or any other signs of hypersensitivity. Patients who are known or suspected to be poor CYP2C9 metabolizers. Concomitant use w/ oral anticoagulants including warfarin/coumarin-type & novel oral anticoagulant (eg, apixaban, dabigatran & rivaroxaban). Avoid concomitant use w/ non-aspirin NSAID. May diminish utility of diagnostic signs in detecting infections eg, fever. Renal toxicity. Moderate hepatic impairment (Child-Pugh class B). Not recommended w/ severe hepatic impairment (Child-Pugh class C). Avoid use during 2nd & 3rd trimester of pregnancy. Lactation.